Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

BACKGROUND: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast cancer receiving chemotherapy. We now present the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Waller, Cornelius F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091175/
https://www.ncbi.nlm.nih.gov/pubmed/33892316
http://dx.doi.org/10.1016/j.breast.2021.03.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091175/
https://www.ncbi.nlm.nih.gov/pubmed/33892316
http://dx.doi.org/10.1016/j.breast.2021.03.009

Ejemplares similares